Aller au contenu principal
2025 conference-paper

Cost-utility and clinical impact of endoscopic screening for gastro-esophageal neoplasia in patients with head and neck neoplasms

0Citations signalées, ce qui n’est pas une note de qualité
3Institutions déclarées
1Pays d’affiliation déclarés

Rattachement africain : pt. Niveau de preuve : code pays fourni par la source.

Le résumé fourni par la source

Aims Patients with head and neck neoplasms (HNN) are at increased risk of gastro-esophageal neoplasia (GEN) due to shared risk factors. Nevertheless, the cost-utility of endoscopic screening in this population has yet to be evaluated. Our aim was to assess the cost-effectiveness of an endoscopic screening strategy in patients with HNN in a Western country (Portugal). Methods In this prospective single-center study, HNN patients eligible for curative treatment underwent screening esophagogastroduodenoscopy (June 2020-December 2023). We assessed the frequency of GEN and associated clinical and pathological outcomes. The cost-effectiveness of synchronous endoscopic screening in these patients was evaluated from a societal perspective (Markov model). The screening strategy was deemed cost-effective if the incremental cost-effectiveness ratio (ICER) was lower than 1-3 times the Portuguese gross domestic product (GDP) per capita (24,646€). To account for uncertainty, we performed probabilistic sensitivity analysis. Results We initially evaluated 207 HNN patients. Forty-six met inclusion criteria and underwent endoscopic screening. In 10 of those (21.7%), a GEN was identified (esophageal neoplasia=5; gastric neoplasia=5). Most patients (n=9) underwent treatment with curative intent. The endoscopic screening strategy had an ICER of 39,357.8€/Quality Adjusted Life Yearsgained, being cost-effective at a willingness-to-pay threshold of two times the Portuguese GDP per capita. In probabilistic sensitivity analysis, screening displayed a 63% probability of being cost-effective considering that willingness-to-pay threshold. Conclusions An endoscopic screening program identified GEN in a fifth of HNN patients, most presenting at an early stage. The program implementation is cost-effective in Portugal. These results may be applicable to most medium/high-income Western countries. Publication History Article published online: 27 March 2025 © 2025. European Society of Gastrointestinal Endoscopy. All rights reserved. Georg Thieme Verlag KG Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Le contrôle bibliographique ouvert

DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.

Titre Crossref
Cost-utility and clinical impact of endoscopic screening for gastro-esophageal neoplasia in patients with head and neck neoplasms
Date Crossref
01/03/2025
Éditeur
Georg Thieme Verlag KG
Type
proceedings-article

Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.

Les institutions déclarées

Une affiliation ne permet pas de déduire la nationalité d’un auteur.

Les sujets associés

Esophageal Cancer Research and TreatmentEsophageal and GI PathologyGastric Cancer Management and Outcomes

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.